Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 2/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18942773 | 0.87 | MAPT (0.64) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL5800857 | 0.86 | JAK3 (0.59) | MAPTKLK7KLK5SYKITGB3 | |
| SCHEMBL14636351 | 0.85 | CTSK (0.56) | MAPTKLK7KLK5MEN1KMT2A | |
| SCHEMBL2467817 | 0.84 | FOLH1 (0.65) | MAPTKLK7KLK5SYKITGB3 | |
| SCHEMBL1491720 | 0.84 | FOLH1 (0.65) | MAPTKLK7KLK5SYKITGB3 | |
| SCHEMBL699636 | 0.84 | FOLH1 (0.65) | MAPTKLK7KLK5SYKITGB3 | |
| SCHEMBL27497192 | 0.84 | KLK7 (0.63) | MAPTKLK7KLK5SYKMEN1 | |
| SCHEMBL30544856 | 0.84 | KLK7 (0.63) | MAPTKLK7KLK5SYKMEN1 | |
| SCHEMBL30043940 | 0.83 | SIRT2 (0.64) | MAPTKLK7KLK5SYKMEN1 | |
| SCHEMBL5328141 | 0.83 | SIRT2 (0.66) | MAPTKLK7KLK5SYKITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227795-A1 | TARGET MOLECULES OF PLADIENOLIDES, COMPOUNDS BINDING TO SUCH TARGET MOLECULES, AND SCREENING METHOD THEREOF | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227795-A1 | TARGET MOLECULES OF PLADIENOLIDES, COMPOUNDS BINDING TO SUCH TARGET MOLECULES, AND SCREENING METHOD THEREOF | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-2053393-A1 | PLADIENOLIDE TARGET MOLECULE, COMPOUND CAPABLE OF BINDING TO THE TARGET MOLECULE, AND SCREENING METHOD FOR THE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227795-A1 | TARGET MOLECULES OF PLADIENOLIDES, COMPOUNDS BINDING TO SUCH TARGET MOLECULES, AND SCREENING METHOD THEREOF | SF3B3, SF3B2, SF3B1 | MAPT 4196/4885KLK7 2140/4885KLK5 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.